Drug intelligence / Profile preview

YHR2404

Development stage: Unknown
Lead developer: Yuhan
Modality: Small Molecules
Administration: Oral

Overview

YHR2404 is an oral pharmaceutical formulation developed as a comparator product in bioequivalence studies. It has been evaluated in clinical trials alongside YHP2305 to determine pharmacokinetic equivalence in healthy volunteers. The specific active ingredient of YHR2404 is not explicitly stated in the available sources, but it is being used as a reference drug for bioequivalence testing, suggesting it may be a generic or alternative formulation of an established medication[1][2][3]. The developer and sponsor of the clinical trial involving YHR2404 is Yuhan.

Beyond the preview

Go deeper on YHR2404.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YHR2404.

Explore the full profile